Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas
Clinical Lymphoma Myeloma and Leukemia · 2026-06 · 26 (6) · 388-398.e3
DOI: 10.1016/j.clml.2026.03.010 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-06. Verfasst von Mingyuan Sun und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Dis…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Proto-Oncogene Proteins c-bcl-2, Lymphoma, Non-Hodgkin, Antineoplastic Agents. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Lisaftoclax is a novel BCL-2 inhibitor. This phase 1 trial (NCT03913949) evaluated the safety and preliminary efficacy of lisaftoclax in Chinese patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other non-Hodgkin lymphomas (NHL). PATIENTS AND METHODS: Lisaftoclax was administered orally in 28-day cycles, targeting daily doses of 20-800 mg for up to 24 cycles, using a daily ramp-up to minimize tumor lysis syndrome (TLS) risk. Patients with previous resistance to a BCL-2 inhibitor or exposure to a BCL-2 inhibitor in the most recent treatment line were excluded. Among 51 enrolled patients, 14 had CLL/SLL, 13 mantle cell lymphoma (MCL), and 4 marginal zone lymphoma (MZL). RESULTS: The maximum tolerated dose of lisaftoclax was not reached; neither dose-limiting toxicity nor TLS was observed. Common adverse events included anemia, neutropenia, and thrombocytopenia. Significant antitumor activity was observed in CLL/SLL (overall response rate [ORR] 71.4%, complete response [CR] 28.6%); MCL (ORR 50.0%, CR 20.0%); and MZL (ORR 50.0%, CR 0). Median progression-free survival was 7.9 (95% CI, 4.9-14.1) months for all patients and 18.6 (95% CI, 8.4-not reached [NR]) and 7.9 (95% CI, 2.0-NR) months for those with CLL/SLL and MCL, respectively. The median overall survival was NR (95% CI, 26.2-NR) for all patients. CONCLUSION: Lisaftoclax has a manageable safety profile and induces durable responses in R/R CLL/SLL and NHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union M…
- Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.
- The First Affiliated Hospital of University of Science and Technology of China (USTC), Anhui Provincial Hospital, Hefei 230001, China.
- Zhongnan Hospital, Wuhan University, Wuhan 430071, China.
- Ascentage Pharma (Suzhou) Co., Ltd., Suzhou 215000, China.
- Ascentage Pharma (Suzhou) Co., Ltd., Suzhou 215000, China; State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, Chi…
Zitieren
APA
Sun, M., Zhou, K., Qi, J., Liu, H., Shen, A., Geng, L., Zhou, F., Huang, J., Chen, Z., Zhang, K., Men, L., Cong, D., Lu, F., Yang, D., Zhai, Y., & Wang, J. (2026). Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas. Clinical Lymphoma Myeloma and Leukemia, 26(6), 388-398.e3. https://doi.org/10.1016/j.clml.2026.03.010
Vancouver
Sun M, Zhou K, Qi J, Liu H, Shen A, Geng L, et al. Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas. Clinical Lymphoma Myeloma and Leukemia. 2026;26(6):388-398.e3. doi:10.1016/j.clml.2026.03.010
BibTeX
@article{Sun2026,
author = {Sun, Mingyuan and Zhou, Keshu and Qi, Junyuan and Liu, Huilan and Shen, Aizong and Geng, Liangquan and Zhou, Fuling and Huang, Jianying and Chen, Zi and Zhang, Ke and Men, Lichuang and Cong, Danhua and Lu, Fang and Yang, Dajun and Zhai, Yifan and Wang, Jianxiang},
title = {Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {6},
pages = {388--398.e3},
doi = {10.1016/j.clml.2026.03.010}
}
EUVIMED